Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma

References 

1. Sober AJ, Lew RA, Koh HK, Barnhill RL. Epidemiology of cutaneous melanoma An update. Dermatol. Clin. 1991;9(4):617–629
   • MEDLINE
2. Cavalieri R, Macchini V, Mostaccioli S, et al.  Time trends in features of cutaneous melanoma at diagnosis, Central-south Italy, 1962-1991. Ann. Ist. Super. Sanita. 1993;29:469–472
   • MEDLINE
3. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith T, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high risk resected malignant melanoma (The Eastern Cooperative Oncology group trial EST 1684). J. Clin. Oncol. 1996;14(1):7–17
   • MEDLINE
4. Pehamberger H, Soyer HP, Steiner A, et al.  Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J. Clin. Oncol. 1998;16(4):1425–1429
   • MEDLINE
5. Grob JJ, Dreno B, de la Salmoniere P, et al.  Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998;351:1905–1910
   • Abstract
   • Full Text
   • Full-Text PDF (88 KB)
   • CrossRef
6. Haycock KA, Roth J, Gagnon J. Statview Statistical Software 1992. Berkeley, CA, Abacus Concept Inc, 1992.
7. Slingluff CL, Dodge RK, Stanley WE, Seigler HF. The annual risk of melanoma progression. Implications for the concept of cure. Cancer. 1992;70:1917–1927
   • MEDLINE
   • CrossRef
8. Institut National de la Statistique et des Etudes Economiques (France) . Annuaire Statistique de la France. Paris: The Institut; 1996;
9. Hakulinen T, Abeywickrama . A computer program package for relative survival analysis. Comput. Methods Programs. Biomed. 1985;19:197–207
10. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics. 1989;45(3):781–795
    • MEDLINE
    • CrossRef
11. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann. Intern. Med. 1991;114:621–628
    • MEDLINE
12. Agence Nationale pour le Développement de l'Evaluation Médicale (France) . Conférence de Consensus (Suivi des Patients Opérés d'un Mélanome de Stade 1). Paris: The Agency; 1995;
13. Union des Caisses Nationales de Sécurité Sociale (France) . Nomenclature Générale des Actes Professionnels. Paris: The Union; 1996;
14. Union des Caisses Nationales de Sécurité Sociale (France) . Tarif Interministériel des Prestations Sanitaires. Paris: The Union; 1996;
15. Mission, P.M.S.I. du Ministère de la Santé (France) . Echelle Nationale des Coûts Relatifs. Paris: The Union; 1995;
16. Ville de Paris (France) . Tarif des Services Hospitaliers de l'Assistance-Publique de Paris. Paris: Bulletin Officiel de la Ville de Paris; 1995;
17. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. 1992;146:473–481
18. Smith TJ, Hillner BE. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J. Clin. Oncol. 1993;11(4):771–776
    • MEDLINE
19. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant Interferon Alfa-2b in high risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J. Clin. Oncol. 1997;15:2351–2358
    • MEDLINE
20. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality of life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma (an Eastern Cooperative Oncology Group Study). J. Clin. Oncol. 1996;14:2666–2673
    • MEDLINE